Gene expression for suppressors of telomerase activity (telomeric-repeat binding factors) in XXXX .

@entity1 @entity0 @entity1420 @entity5 @entity64710 @entity7071
Mechanisms regulating telomerase activity and telomere length remain incompletely understood in @entity1 @entity0 . We therefore studied gene expression for telomeric-repeat binding factors (TRFs) in relation to telomerase activity, telomere length, and clinicopathologic factors in @entity1 @entity0 . Telomerase activity was detected in 65.8% of 38 @entity0 , but none of 16 noncancerous samples. Terminal restriction fragments were longer in noncancerous than in cancerous tissues, but not significantly. Among 8 @entity1 with both @entity5 and paired noncancerous tissue available for terminal restriction fragments length assay, terminal restriction fragments were @entity5 than in paired noncancerous samples in all but one. Significantly more mRNA encoding @entity64710 was detected in noncancerous than in @entity5 tissues. Additionally, expression of @entity64710 mRNA was significantly higher in @entity5 without detectable telomerase activity than in @entity5 showing activity. Expression of these genes tended to show a negative correlation with terminal restriction fragments length, but this was not statistically significant. No correlation was seen between @entity7071 or 2 mRNA expression, and clinicopathologic factors except for @entity7071 with respect to @entity5 size and @entity1420 receptor status. In addition to reactivation of telomerase activity, escape from negative regulation of this activity is needed to maintain telomere length during cell proliferation in @entity0 . Genes encoding telomerase inhibitors might be of value in gene therapy against @entity1 @entity0 .
